TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03949673

Intervention type: DRUG
Group type: OTHER
Intervention: Fasinumab
Description: Study drug will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study

Intervention type: DRUG
Group type: OTHER
Intervention: Naproxen
Description: Naproxen will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study

Intervention type: DRUG
Group type: OTHER
Intervention: Diclofenac
Description: Diclofenac will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study

Intervention type: DRUG
Group type: OTHER
Intervention: Celecoxib
Description: Celecoxib will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matching Placebo will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Study: NCT01144273

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: This intraabdominal approach to TAP block is being used regularly by gynaecological surgeons in this hospital now.~To be performed bilaterally before surgical wound closure by an experienced surgeon who initially undergo initial observation by investigator to ensure uniformity in technique.~Local anaesthetic or placebo solution will be injected to TAP with blunt needle from within abdominal cavity under visual and tactile guidance at the triangle of Petit, after feeling one 'pop' through the transversus abdominis muscle to the TAP layer.~After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0.5% ropivacaine or 0.3ml/kg of 0.9% saline placebo will be injected to each side slowly while observing for signs of toxicity.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversus abdominis plane block
Description: This intraabdominal approach to TAP block is being used regularly by gynaecological surgeons in this hospital now.~To be performed bilaterally before surgical wound closure by an experienced surgeon who initially undergo initial observation by investigator to ensure uniformity in technique.~Local anaesthetic or placebo solution will be injected to TAP with blunt needle from within abdominal cavity under visual and tactile guidance at the triangle of Petit, after feeling one 'pop' through the transversus abdominis muscle to the TAP layer.~After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0.5% ropivacaine or 0.3ml/kg of 0.9% saline placebo will be injected to each side slowly while observing for signs of toxicity.
Study: NCT04391140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone position
Description: HFNC set to a SpO2 of 90-95% combined with prone position. At least 2 sessions of 30 minutes or more will be performed daily.
Study: NCT01999829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citrate of caffeine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01583036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin Alone
Description: Single administration of digoxin 0.25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin + Retigabine
Description: Increasing doses of retigabine (300mg, 450mg, 600mg, 750mg, 900mg, 1050mg and 1200mg) administered as TID doses over 44 days. Co-administration with digoxin (0.25mg) on days 10, 24 and 38.
Study: NCT04152759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: BAT2506 injection Other Names: Simponi(EU-licensed)
Description: Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).~Other Names:~Simponi(EU-licensed)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: BAT2506 injection Other Names: Simponi(EU-licensed)
Description: Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).~Other Names:~Simponi(EU-licensed)
Study: NCT02625402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief interactive decision aid
Description: The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long video decision aid
Description: Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
Study: NCT03026725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tri-calcium Phosphate
Description: A paste contains Tri Calcium Phosphate \& Fluoride

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: paste manufactured to mimic Clinpro, without Tri Calcium Phosphate
Study: NCT03990753

Intervention type: DIAGNOSTIC_TEST
Intervention: esophagogastroduodenoscopy
Description: standard esophagogastroduodenoscopy
Study: NCT00709670

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MSCT and stress echocardiography
Description: tests MSCT and stress echocardiography
Study: NCT00580086

Intervention type: OTHER
Intervention: MR spectroscopy
Description: (1H MRS) on 1.5 Tesla (1.5T), using a software package from General Electric Medical Systems, Milwaukee, WI
Study: NCT05446844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A nurse caring behavior protocol
Description: Nursing interventions based on caring behaviors protocol was provided as follows:~* Caring behaviors during ICU admission and orientation processes included orienting patients to time, place, and person.~* Caring behaviors during physical care informing patients regarding the purpose and expected duration of mechanical ventilator use.~* Caring behaviors during psychological care included offering religious sound meditation.~* Caring behaviors during social interaction included maintaining eye contact during nurse-patient interaction.~* Caring behaviors during health teaching included providing health teaching for patients.~* Caring behaviors during maintaining a safe healing environment included providing patients with an explanation regarding nursing activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine nursing care
Description: Routine nursing care was concentrated mainly on hard skills of physically demanding care such as monitoring vital signs.
Study: NCT06532916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group1: Estelite Sigma Quick
Description: Preheated conventional composite (Estelite Sigma Quick, Tokuyama Dental Corp, Tokyo, Japan). Estelite Sigma Quick is a resin composite with the following composition (Silica-zirconiasupra-nano, monodispersingc spherica, Bis-GMA, UDMA, TEGDMA).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group1: Estelite Sigma Quick
Description: Preheated conventional composite (Estelite Sigma Quick, Tokuyama Dental Corp, Tokyo, Japan). Estelite Sigma Quick is a resin composite with the following composition (Silica-zirconiasupra-nano, monodispersingc spherica, Bis-GMA, UDMA, TEGDMA).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group 2: Estelite Flow Quick
Description: Second group: Injectable flowable (Estelite Flow Quick, Tokuyama Dental Corp, Tokyo, Japan). Estelite Flow Quick is a resin composite with the following composition (Silica-zirconia, supra-nano monodispersing spherical, Bis-GMA, UDMA,TEGDMA).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group 2: Estelite Flow Quick
Description: Second group: Injectable flowable (Estelite Flow Quick, Tokuyama Dental Corp, Tokyo, Japan). Estelite Flow Quick is a resin composite with the following composition (Silica-zirconia, supra-nano monodispersing spherical, Bis-GMA, UDMA,TEGDMA).
Study: NCT00315575

Intervention type: PROCEDURE
Intervention: BOLD and Perfusion brain MRI
Description: Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour

Intervention type: PROCEDURE
Intervention: BOLD and Perfusion brain MRI
Description: Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
Study: NCT00500890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 350 mg/m\^2 by vein, Over 2 Hours x 2 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1 g/m\^2 by vein, Over 1 Hour x 2 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 by vein, Over 1 Hour x 5 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 by vein, Over 1 Hour x 5 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m\^2 (by vein)IV Push Over 15 Minutes On Day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m\^2 (by vein)IV Push Over 15 Minutes On Day 5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatment over a period of about 6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatment over a period of about 6 weeks.
Study: NCT01325766

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Yoga 2 sessions per week for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Yoga 2 sessions per week for 8 weeks
Study: NCT02260622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban plus aspirin
Description: Rivaroxaban 2.5 mg twice daily for 90 days (rivaroxaban will be started 6 to 8 hours after the finalization of the procedure) and 81 mg of ASA daily for 90 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel plus aspirin
Description: Clopidogrel 75 mg daily for 90 days (with a loading dose of 300 mg clopidogrel following PTA) and 81 mg of ASA daily for 90 days
Study: NCT03549195

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICG
Description: The ICG powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICG-CP
Description: The ICG-CP powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG-TMTP1
Description: The ICG-TMTP1 powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
Study: NCT03407586

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point-of-care STI testing
Description: All participants underwent point-of-care STI testing (GeneXpert), and if diagnosed with a STI were offered immediate therapy, and expedited therapy, if indicated.
Study: NCT05252260

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgery
Description: A local anesthetic was administered bilaterally to the mental area and waited for 5 min for diffusion of the solution. Then, a horizontal incision was prepared at the mucogingival junction with a scalpel blade no. 15c. All the muscle fibers over the periosteum were resected carefully. Following, the mucosal flap was sutured to the depth of the vestibule sulcus with 4-0 polypropylene suture material, once every 4 mm, from a total of 5 regions.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Surgery
Description: A local anesthetic was administered bilaterally to the mental area and waited for 5 min for diffusion of the solution. Then, a horizontal incision was prepared at the mucogingival junction with a scalpel blade no. 15c. All the muscle fibers over the periosteum were resected carefully. Following, the mucosal flap was sutured to the depth of the vestibule sulcus with 4-0 polypropylene suture material, once every 4 mm, from a total of 5 regions.

Intervention type: OTHER
Group type: OTHER
Intervention: Low level laser therapy (LLLT)
Description: Vestibuloplasty surgery was performed via diode laser. Following, LLLT was applied in continuous wave mode for 1 minute without contacting the tissue, using a phototherapy probe (power output, 0.5W; total energy of 6 J / cm²) at a distance of 1-2 mm from the tissue. LLLT was repeated immediately after the surgery, on the 1st, 3rd and 7th days
Study: NCT00845000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
Study: NCT02487836

Intervention type: DEVICE
Group type: OTHER
Intervention: Type WallFlex or Evolution biliary, stent system
Description: Laying of a stent biliary
Study: NCT03650270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Description: Three repeated doses of pareneteral phenobarbital was compared to a single parenteral infusion of phenytoin followed by an infusion of parenteral midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital
Description: Three repeated doses of pareneteral phenobarbital was compared to a single parenteral infusion of phenytoin followed by an infusion of parenteral midazolam
Study: NCT00932711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational brochures
Description: A locally developed educational brochure containing information about smoking cessation, influenza and pneumococcal vaccination, regular exercise, compliance with prescribed COPD therapy and recognition of symptoms, along with a goal setting questionnaire
Study: NCT01617109

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ca/Vit D
Description: 800IU vitamin D3 and 2000mg elemental calcium (as calcium carbonate); administered as 5 pills daily or 2 snack bars

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered as 5 pills daily or as 2 snack bars
Study: NCT03910946

Intervention type: DRUG
Intervention: Tuberculin, Purified Protein 5Unt/0.1 mL Solution
Description: Tuberculosis (diagnosis)-Tuberculin, purified protein derivative (PPD) is indicated as a diagnostic aid in the detection of Mycobacterium tuberculosis infection. It is also indicated when BCG vaccination or isoniazid prophylaxis is being considered
Study: NCT01631253

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian cyst enucleation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian cyst enucleation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian cyst enucleation
Study: NCT04475510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiplatelet treatment discontinuation
Description: All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
Study: NCT03572218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BWL
Description: The BWL sessions will be based on the Diabetes Prevention Program (DPP) manual. A diet of 1200-1499 calories per day will be prescribed for participants \< 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 12 weeks will include self-monitoring, stimulus control, slowing eating, social support, cognitive restructuring, portion sizes, and goal-setting. Those during weeks 13-26 will focus on continued self-monitoring and skills required for weight loss maintenance and relapse prevention. Physical activity will be prescribed at a level consistent with data showing that \>250 min/wk is associated with improved long-term weight loss. BWL sessions will last 60 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BWL
Description: The BWL sessions will be based on the Diabetes Prevention Program (DPP) manual. A diet of 1200-1499 calories per day will be prescribed for participants \< 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 12 weeks will include self-monitoring, stimulus control, slowing eating, social support, cognitive restructuring, portion sizes, and goal-setting. Those during weeks 13-26 will focus on continued self-monitoring and skills required for weight loss maintenance and relapse prevention. Physical activity will be prescribed at a level consistent with data showing that \>250 min/wk is associated with improved long-term weight loss. BWL sessions will last 60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BIAS
Description: Following 60 minutes of BWL treatment, the BIAS intervention will devote 30 minutes to stigma-related content. Session topics will include: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to weight management. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies in the context of weight management.
Study: NCT06305325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth Antenatal Coparenting Intervention
Description: This intervention focuses on developing conflict management, problem solving, communication, and mutual support to foster positive joint parenting of an infant. A modification in the delivery of this intervention was made in the current study in order to make it deliver online. The eACoP intervention included eight antenatal videos from Feinberg's Family Foundation intervention. A website for the eACoP intervention was developed, and all the videos were uploaded to the website. These videos were 30-40 minutes each. The videos were in English and subtitles in Urdu were added to the videos. These videos were accompanied by an activity-based coparenting workbook. The coparenting workbook includes a worksheet and homework for each video and was also translated into Urdu
Study: NCT01955018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA)
Description: The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality.

Intervention type: DEVICE
Group type: OTHER
Intervention: New algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA)
Description: The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality.
Study: NCT01350973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3-acid ethyl esters 90 (TAK-085)
Description: Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3-acid ethyl esters 90 (TAK-085)
Description: Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid-ethyl (EPA-E)
Description: EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.
Study: NCT01094093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 139
Description: Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers (Part A) and subjects with moderate-severe psoriasis (Part B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 139
Description: Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers (Part A) and subjects with moderate-severe psoriasis (Part B).
Study: NCT01845857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Workshop
Description: 6 week, small group self-management workshop
Study: NCT00578526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SU011248
Description: 50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg capsule OD PO for 28 days then 14 days rest until disease progression
Study: NCT03018730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRX-102 (pegunigalsidase alfa)
Description: PRX-102 1 mg/kg every 2 weeks
Study: NCT03022448

Intervention type: OTHER
Intervention: No Intervention
Description: This is a NIS. No intervention.
Study: NCT03362593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7219
Description: Experimental Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Formulation without Active Drug
Description: Formulation without Active Drug
Study: NCT02492386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioabsorbable everolimus-eluting stent deployment
Description: Bioabsorbable everolimus-eluting stent deployment
Study: NCT02054949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine (NAC)
Description: NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.